. 2023 Aug 31;202(3):563–573. doi: 10.1007/s10549-023-07078-9

Table 1.

Summary of somatic mutations (SNVs, short indels) in the five metaplastic carcinomas analyzed in this study

Sample	Number of all mutations	Number of nonsynonymous mutations	Pathogenic nonsynonymous mutations
LGASC	275	13	GNAS(c.C2530T:p.R844C)^a
LNMSC	1118	30	GNAS(c.C2530T:p.R844C)^a
M2T	2233	29	TP53(c.C535T:p.H179Y)^a
M2T	2233	29	PIK3CA(c.1255-1260del:p.419-420del)
M3T	5167	93	TP53(c.C318G:p.S106R)
M4T	2609	45	PIK3CA(c.G1624A:c.p.E542K)^a
			ERBB2(c.G2329T:p.V777L)^a
			HRAS(c.G34A:p.G12S)^a

LGASC, low-grade adenosquamous carcinoma; LNMSC, lymph node metastasis consisting of high-grade metaplastic carcinoma of the breast with a predominant metaplastic squamous cell carcinoma component

^aHotspot mutations